A mechanistic understanding of cancer rests heavily upon the mutated genes. These include genes causing familial tumor susceptibilities, governing replication fidelity, and residing in regulatory pathways. Pancreatic cancer is an unusually efficient system in which to identify distinctive mutational targets, discoveries to which our research group has contributed heavily. This success is due in part to highly informative structural patterns of homozygous deletions as well as a higher incidence of genome-maintenance mutations (especially those affecting homologous recombination) in this tumor type. Indications are that many recessive genes and perhaps additional dominant genes remain to be discovered in pancreatic cancer. Most of the high-risk pancreatic cancer families remain unexplained by known mutations, and most cancers having CIN (chromosomal instability) are not yet tied mechanistically to a molecular cause. Recessive mutations in novel genes, for example, are currently being discovered more rapidly than can be annotated for their functional significance. We recently explored and published key technical breakthroughs and special tumor cell resources that are newly available and can quickly accelerate this line of study. Powerful high-throughput sequencing techniques are underway to aid such studies, but will need to be complemented by a roadmap derived from a strategic structural analysis of the cancer genome such as we are developing.
Our specific aims will locate promising sites of new mutant genes. For genes having some existing functional clues, we can assess the effects of mutation using available assays. For truly novel genes having few clues as to their function, we can achieve missense mutations or gene disruption using technologies we developed for homologous recombination in somatic cells, with phenotypic assessment accomplished both by gene-specific assays and by orthotopic xenografting. For genes having unknown functional assignment and distant evolutionary conservation, a zebrafish model of gene impairment will be used to survey for developmental clues to function and for an ability to augment zebrafish pancreatic tumorigenesis. This latter technique seems surprising, but appears to offer immense efficiency for classifying novel genes. Our long-term goal is to provide a more complete foundation for future studies of familial susceptibility, disrupted signaling pathways, and genome instability in pancreatic cancer.

Public Health Relevance

Pancreatic cancer is a genetic disease caused by mutations. We identified frequent mutations in the p16, SMAD4, BRCA2, and other genes, explaining the causes of many cases of familial forms of pancreatic cancer. We now need to efficiently survey large numbers of mutated genes arising through new technologies. These genes and techniques will be explored in this project

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Park, J T; Johnson, N; Liu, S et al. (2015) Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey. Oncogene 34:2801-6
Rakheja, Dinesh; Chen, Kenneth S; Liu, Yangjian et al. (2014) Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun 2:4802
Matthaei, Hanno; Wu, Jian; Dal Molin, Marco et al. (2014) GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". Am J Surg Pathol 38:360-3
Chivukula, Raghu R; Shi, Guanglu; Acharya, Asha et al. (2014) An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. Cell 157:1104-16
McAllister, Florencia; Bailey, Jennifer M; Alsina, Janivette et al. (2014) Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25:621-37
Bailey, Jennifer M; Alsina, Janivette; Rasheed, Zeshaan A et al. (2014) DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 146:245-56
Krzeszinski, Jing Y; Wei, Wei; Huynh, HoangDinh et al. (2014) miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 512:431-5
Patel, Kalpesh; Kern, Scott E (2013) "Selective cell death mediated by small conditional RNAs" is not selective. Cancer Biol Ther 14:693-6
Streppel, Mirte Mayke; Pai, Shweta; Campbell, Nathaniel R et al. (2013) MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res 19:4067-78
Mendell, Joshua T; Olson, Eric N (2012) MicroRNAs in stress signaling and human disease. Cell 148:1172-87

Showing the most recent 10 out of 35 publications